APA

Ledermann J. A., Harter P., Gourley C., Friedlander M., Vergote I., Rustin G., Scott C., Meier W., Shapira-Frommer R., Safra T., Matei D., Fielding A., Spencer S., Rowe P., Lowe E., Hodgson D., Sovak M. A. & Matulonis U. (20170526). Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. : The Lancet. Oncology.

Chicago

Ledermann Jonathan A, Harter Philipp, Gourley Charlie, Friedlander Michael, Vergote Ignace, Rustin Gordon, Scott Clare, Meier Werner, Shapira-Frommer Ronnie, Safra Tamar, Matei Daniela, Fielding Anitra, Spencer Stuart, Rowe Philip, Lowe Elizabeth, Hodgson Darren, Sovak Mika A and Matulonis Ursula. 20170526. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. : The Lancet. Oncology.

Harvard

Ledermann J. A., Harter P., Gourley C., Friedlander M., Vergote I., Rustin G., Scott C., Meier W., Shapira-Frommer R., Safra T., Matei D., Fielding A., Spencer S., Rowe P., Lowe E., Hodgson D., Sovak M. A. and Matulonis U. (20170526). Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. : The Lancet. Oncology.

MLA

Ledermann Jonathan A, Harter Philipp, Gourley Charlie, Friedlander Michael, Vergote Ignace, Rustin Gordon, Scott Clare, Meier Werner, Shapira-Frommer Ronnie, Safra Tamar, Matei Daniela, Fielding Anitra, Spencer Stuart, Rowe Philip, Lowe Elizabeth, Hodgson Darren, Sovak Mika A and Matulonis Ursula. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. : The Lancet. Oncology. 20170526.